Biotech Values

[vinmantoo]

ENTA—Even now, the market is ascribing essentially zero value to the RSV and immunology programs. That's why I'm holding all of my shares despite having an outsized position.

My feelings exactly. Before today ENTA had enough cash to to fund operations for more than 2 years. After the RSV data release today, the prospects for a partnership if not a buyout have risen significantly. If neither materializes at a price ENTA management consider fair, is it beyond the realm of possibility for ENTA to raise money and proceed to phase 3 in RSV on its own and or move EDP-323 into a phase 2 trial? That unlikely possibility would require ENTA to jump to a much higher price than the current $15/share. FYI, I would much prefer a buyout or partnership.